Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Huaren Pharmaceutical Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Huaren Pharmaceutical CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xiaodong Yang	Chairman & President	5.2yrs	CN¥3.12m	0.11% CN¥ 4.8m
Yang Li	Non-Independent Director	5.2yrs	Veri yok	Veri yok
Genfu Feng	Independent Director	5.2yrs	CN¥100.00k	Veri yok
Tianxi Zhang	Independent Director	5.2yrs	CN¥100.00k	Veri yok
Li Qiang	Chairman of the Supervisory Board	5.2yrs	Veri yok	Veri yok
Xuefei Jia	Supervisor	2.5yrs	Veri yok	Veri yok
Subin Zhu	Non-Independent Director	2.5yrs	Veri yok	Veri yok
Chuanwen Dong	Non-Independent Director	2.5yrs	Veri yok	Veri yok
Yong Liu	Independent Director	2.8yrs	Veri yok	Veri yok
Zhihua Huang	Non-Independent Director	1.1yrs	Veri yok	Veri yok
Yan Dong	Non-Independent Director	1.1yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300110 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Huaren Pharmaceutical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024

High number of new directors

Huaren Pharmaceutical Co., Ltd. Announces Director Appointments

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2023

High number of new and inexperienced directors

Huaren Pharmaceutical Co., Ltd. Approves Board Appointments

Recent updates

Investor sentiment improves as stock rises 29%

Huaren Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New minor risk - Financial position

Dividend of CN¥0.021 announced

Huaren Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

New minor risk - Dividend sustainability

Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.035 in 1Q 2023)

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024

Now 20% undervalued after recent price drop

Huaren Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

New minor risk - Profit margin trend

Huaren Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

High number of new directors

Huaren Pharmaceutical Co., Ltd. Announces Director Appointments

New minor risk - Profit margin trend

Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2023

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.041 (vs CN¥0.041 in 2Q 2021)

Investor sentiment improved over the past week

Huaren Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

High number of new and inexperienced directors

Huaren Pharmaceutical Co., Ltd. Approves Board Appointments

Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.11 (vs CN¥0.08 in FY 2020)

Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Third quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.016 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.025 in 2Q 2020)

Huaren Pharmaceutical Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2020, Payable on June 4, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.005 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.08 (vs CN¥0.036 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.08 (vs CN¥0.036 in FY 2019)

Huaren Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 20, 2021

New 90-day low: CN¥4.28

New 90-day low: CN¥4.55

New 90-day low: CN¥4.89

Huaren Pharmaceutical Co., Ltd. (SZSE:300110) agreed to acquire Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd. from Ruan Chuanming, Ruan Yingle and He Hui for approximately CNY 390 million.

Third quarter earnings released

Huaren Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥4.89

First half earnings released

New 90-day high - CN¥4.79

Huaren Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş